Mejia JA - Search Results

1

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Liedtke C, et al. Among authors: mejia ja. J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4. J Clin Oncol. 2008. PMID: 18250347 Corrected and republished.

2

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Hess KR, et al. Among authors: mejia ja. J Clin Oncol. 2006 Sep 10;24(26):4236-44. doi: 10.1200/JCO.2006.05.6861. Epub 2006 Aug 8. J Clin Oncol. 2006. PMID: 16896004

3

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Gong Y, et al. Lancet Oncol. 2007 Mar;8(3):203-11. doi: 10.1016/S1470-2045(07)70042-6. Lancet Oncol. 2007. PMID: 17329190

4

Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.

Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Andre F, et al. Clin Cancer Res. 2007 Apr 1;13(7):2061-7. doi: 10.1158/1078-0432.CCR-06-2078. Clin Cancer Res. 2007. PMID: 17404087 Free article.

5

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.

Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. Esteva FJ, et al. Among authors: mejia ja. Breast Cancer Res. 2007;9(6):R87. doi: 10.1186/bcr1836. Breast Cancer Res. 2007. PMID: 18086299 Free PMC article.

6

Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival.

Beinart G, Gonzalez-Angulo AM, Broglio K, Mejia J, Ruggeri A, Mininberg E, Hortobagyi GN, Valero V. Beinart G, et al. Clin Breast Cancer. 2007 Dec;7(11):867-74. doi: 10.3816/CBC.2007.n.052. Clin Breast Cancer. 2007. PMID: 18269777

7

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.

Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Rivera E, et al. Among authors: mejia ja. Cancer. 2008 Apr 1;112(7):1455-61. doi: 10.1002/cncr.23321. Cancer. 2008. PMID: 18300256 Free article. Clinical Trial.

8

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Peintinger F, et al. Among authors: mejia ja. Ann Oncol. 2008 Dec;19(12):2020-5. doi: 10.1093/annonc/mdn427. Epub 2008 Jul 29. Ann Oncol. 2008. PMID: 18667396 Free PMC article.

9

Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule.

Estephan F, Valero V, Esteva FJ, Mejia JA, Frye DK, Ibrahim NK. Estephan F, et al. Among authors: mejia ja. Oncology. 2009;77(1):63-70. doi: 10.1159/000226213. Epub 2009 Jun 26. Oncology. 2009. PMID: 19556811 Clinical Trial.

10

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.

Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Winer EP, et al. Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4. Lancet Oncol. 2021. PMID: 33676601 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

83 results

Search Page